NEWS
GA_P advises Vista Equity Partners on €2.425m acquisition of Duck Creek
10 of January, 2023
GA_P has advised investment fund Vista Equity Partners on the Spanish leg of the acquisition of Duck Creek Technologies (NASDAQ: DCT) to delist it from the stock exchange.
Vista Equity Partners has reached an agreement with technology company Duck Creek Technologies to acquire it for a total of $2.6 billion (€2.425 billion) in cash. The deal is expected to close in the second quarter of 2023, subject to the satisfaction of certain conditions customary in such transactions, after which the entity will be delisted.
Duck Creek specialises in providing customer management software products to insurance companies and broker-dealers.
Vista Equity Partners is a leading global investment fund investing in enterprise software, data and technology companies.
They advised on the transaction: Alex Pujol, partner of Commercial, Andrea Esbrí, senior associate of Commercial, Mònica Martells, associate of Commercial, and Anna Viladás and Paula Ruiz Cotorro from Industrial Property, Intellectual Property and Technology.
Vista Equity Partners has reached an agreement with technology company Duck Creek Technologies to acquire it for a total of $2.6 billion (€2.425 billion) in cash. The deal is expected to close in the second quarter of 2023, subject to the satisfaction of certain conditions customary in such transactions, after which the entity will be delisted.
Duck Creek specialises in providing customer management software products to insurance companies and broker-dealers.
Vista Equity Partners is a leading global investment fund investing in enterprise software, data and technology companies.
They advised on the transaction: Alex Pujol, partner of Commercial, Andrea Esbrí, senior associate of Commercial, Mònica Martells, associate of Commercial, and Anna Viladás and Paula Ruiz Cotorro from Industrial Property, Intellectual Property and Technology.
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
¡NEW! 
PUBLICATION
Pharma & Healthcare No. 40
¡NEW! 
PUBLICATION
Inside Information and Quarterly Financial Statements: CNMV Communication of 13 October 2021
The CNMV notes in this communication that, although there are no closed periods in respect of the voluntary publication by issuers of the quarterly financial report, this report may contain inside information, in which case the Market Abuse Regulation applies
18 Oct, 2021
PUBLICATION
Digital Content and Services – New consumers and users’ rights
Last week on 27 April, Royal Decree-act 7/2021 of 27 April on the transposition of European Union directives on competition, prevention of money laundering, credit institutions, telecommunications, tax measures, prevention and repair of environmental damage, movement of employees in the provision of transnational services and consumer defence (“RDL 7/2021”).
18 May, 2021
PUBLICATION
Administrative liability of the members of a listed company’s audit committee for serious errors or inaccuracies in the audited annual accounts
The Supreme Court's judgment of 8 October 2020 confirms the administrative liability of Audit Committee members for the inaccuracy or lack of veracity of consolidated annual accounts that have been externally audited
13 Nov, 2020
PUBLICATION
Life Sciences Newsletter No. 9
OJ L 115 of 4 May 2018 publishes Commission Regulation (EU) 2018/669 of 16 April 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32018R0669&from=EN
01 Aug, 2018
PUBLICATION
Publicidad de medicamentos, ficha técnica y menciones distintas de las indicaciones terapéuticas
Al hilo de la Sentencia núm. 186/2018 de la Audiencia Provincial de Barcelona (Sección 15.ª) se examina tanto la necesidad de que la publicidad de los medicamentos se ajuste a la ficha técnica como la posibilidad de incluir en el mensaje publicitario menciones distintas de las indicaciones terapéuticas del medicamento.
16 Jul, 2018
PUBLICATION
Current Legislation No. 24
GA_P’s Current Legislation digests seek to provide an overview of the main legal issues of interest to our readers, clients and lawyers in a format that combines three elements: topicality, clarity and quality. Topicality in the information and in the selection of matters discussed; clarity in laying the foregoing in a concise and intelligible manner rather than...
10 Jul, 2018
PUBLICATION
Payment periods disallowed under the Late Commercial Payments Act: inappropriate voidness
We are accustomed to hearing the assertion that a bilaterally agreed clause contravening the statutory rule setting a time limit for commercial payments is void ab initio. But is this case when it is the supplier who has the bargaining power? And, in general, does such an assertion make sense?
05 Jul, 2018
PUBLICATION
¿Qué sector de público hay que tener en cuenta para determinar si se ha vulgarizado una marca farmacéutica?
1. La vulgarización como causa de caducidad de una marca 1.1. Una de las causas de caducidad de una marca que se prevén en las legislaciones europea y española es la de la conversión del signo que conforma la marca en la designación usual de un producto o de un servicio para el que está...
04 Jun, 2018